Multi-drug resistant Salmonella typhi: why should African countries move quickly toward adopting typhoid conjugate vaccine

preprint OA: closed CC-BY-4.0
🔓 Open OA copy View at publisher

Abstract

Africa has a high burden of typhoid fever causing significant morbidity and mortality especially among children. Over the years there has been increased development of Multi-drug and Extensively drug resistance typhoid strains in the continent which threatens typhoid treatment. This is compounded by a background that most African countries have limited diagnostic capacity, leading to high empiric use of antibiotics, and worsening of antimicrobial resistance.  Access to safe drinking water, hygiene and sanitation facilities also remains a significant challenge for most countries. In this policy brief, we encourage African countries to consider quick adoption of highly efficacious and cost-effective available typhoid conjugate vaccines.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-26T02:00:01.498150+00:00
License: CC-BY-4.0